C-NUBHArrive Bio
in vivo screening, machine learning, bioinformatics
discoverydiscoveringsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-NUBH
C-NUBHC-NUBHin vivo screening, machine learning, bioinformatics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Arrive presents the belief that better health outcomes can be achieved by analyzing biology at the single-cell level, using multi-omics, optical cell data, and AI-driven pathology to uncover hidden patterns that improve drug research and development. The company also frames high-quality training data, large-scale physician-validated pathology networks, and standards for AI in pathology as essential to building accurate population-level precision medicine systems.
SourceArrive states that improving healthspan requires better target discovery for age-related diseases, and that traditional in-vitro pharma assays miss the complex whole-body interactions that drive these conditions. The company claims in-vivo target screening, combined with machine learning, bioinformatics, and a proprietary knowledge database, can make target discovery more feasible and produce better large-scale decisions. It also frames liver, muscle, and brain decline as age-related systems where function can be improved or partially restored, implying preventative or restorative therapies are discoverable.
SourceArrive states that improving healthspan requires a new target-discovery approach for age-related diseases because traditional in vitro pharma assays miss the complex whole-organism interactions that drive these conditions. The company presents in vivo target screening, combined with machine learning, bioinformatics, and a proprietary knowledge database, as the way to make better large-scale decisions, reveal actionable biological patterns, and enable preventative or restorative therapies across organs affected by aging.
SourceArrive states that improving healthspan requires better target discovery for age-related diseases, and that traditional in-vitro pharma discovery is insufficient because it fails to capture the complex interactions underlying those diseases. The company presents in vivo target screening, combined with machine learning, bioinformatics, and a proprietary knowledge database, as a more effective way to identify therapeutic targets. It also frames complex biologic data as requiring advanced computational systems that can extract meaningful patterns and support better large-scale decisions.
SourceArrive states that improving healthspan requires better target discovery for age-related diseases, and that traditional in-vitro pharma discovery misses the complex organism-level interactions involved in aging. The company presents in vivo target screening, combined with machine learning, bioinformatics, and a proprietary knowledge database, as the way to uncover actionable targets from complex biological data and enable more effective preventative or therapeutic interventions.
SourceThe visible snapshot text states that Archive Team believes preserving copies of endangered or deleted websites is important for history and digital heritage, and that duplicating threatened data allows public conversation, debate, and insight to continue even after the original material is removed.
Source